- News
News
Welcome to the homepage of AIHTA!
AIHTA is an acadmic non-profit institute. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the AIHTA team.
In the News section you will find our most recent publications: newsletter, project-reports etc. Previous reports you might find via Research areas, Research projects and Repository.
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: Ende der Pandemie: Eine offene, kritische und konstruktive „Nachbesprechung“ ist unverzichtbarer Teil
- Genexpressionsanalysen bei Brustkrebs im Frühstadium
- Sponsoring von Patient*innen-Initiativen in Österreich
- Vergütung von Hausärzt*innen im Ländervergleich
- PET/PET-CT: Evidenz zum Bedarf und zur Planung bei onkologischen Indikationen
- Termine
- Themen-Vorschau
Announcement
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you one new Fact Sheets.
Fact Sheet No. 129 (April 2023)
Lisocabtagene maraleucel (Breyanzi®) for the treatment of diffuse large B-cell lymphoma (DLBCL), high grade B cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B)
Announcement
Sponsoring of patient initiatives in Austria.5th Update of the Systematic Analyses 2014 to 2019
As patient initiatives expand their activities and continue to professionalise, their need for financial resources, which often gets bankrolled by pharma-ceutical companies, increases accordingly. To make these financial transactions more transparent, the pharmaceutical industry responded with volun-tary disclosure commitments. AIHTA (then still as LBI-HTA) systematical-ly analysed the content of these voluntary disclosures of sponsorship for pa-tient initiatives by members of the Association of Austria’s Pharmaceutical Industry (PHARMIG - Verband der pharmazeutischen Industrie Österreichs) for the first time in 2014 and aims to carry out regular and consistent moni-toring of these payments. The present fifth update systematically researched the extent of financial support to patient initiatives disclosed by member companies of PHARMIG for the fiscal year of 2021.
Publication: Policy Brief No. 007/5. Update: https://eprints.aihta.at/1443/
Contakt: Claudia Wild
Announcement
Oral and parenteral preexposure prophylaxis (PrEP) to prevent HIV in people at risk: a systematic review of clinical effectiveness and safety with assessment of organisational, economic, patients/social, ethical and legal elements
Preexposure prophylaxis (PrEP) is an antiretroviral therapy-based HIV prevention strategy to prevent HIV infection in people who have not been infected with the virus but are at high risk of infection. The report aimed to provide an update evidence synthesis based on a systematic literature search regarding the effectiveness and safety of in the EU and/ or US approved oral and parenteral PrEP pharmaceutical to prevent HIV infection in populations at risk. Additionally, the report addressed organisational, economic, patient/social, ethical and legal aspects to support evidence-based decision-making process on PrEP in Austria.
Publication: HTA Project Report No. 152: https://eprints.aihta.at/1436/
Contact: Inanna Reinsperger
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: Environmental Impact: wie können Umweltaspekte in die Bewertung medizinischer Technologien einbezogen werden
- Entscheidungsunterstützung im Rahmen der Prävention bei BRCA1/2-Mutationsträgerinnen
- Rehabilitationsmodelle und -ansätze für junge Menschen mit Anpassungsschwierigkeiten
- Früherkennung und Versorgung peripartaler psychischer Erkrankungen in Österreich
- Orale und parenterale Prä-Expositionsprophylaxe (PrEP) zur Prävention von HIV-Infektionen bei Personen mit hohem Infektionsrisiko
- Termine
- Themen-Vorschau
Announcement
Update PET/PET-CT evidence for need based planning in the area of oncology
This report is based on that of the LBI-HTA of 2015 and the updates of 2018 and 2020. Various guideline databases and policies were searched to identify the recommended oncological indications for the use of PET/PET-CT applications. In addition to guideline databases, recommendations and non-recommendations from professional societies were considered.
The guideline search identified a total of 122 recommendations regarding the use of PET. The majority of the recommendations (n=112) resulted from the guideline search and database search of national professional societies. The search in supranational professional societies resulted in 10 recommendations. A further 36 recommendations were directed against the use of PET ("inappropriate" cancer indications).
The overall recommendations of the present 2023 update (as in the previous year's 2015 & 2018 reports, as well as the 2020 update) indicate little benefit from PET as a primary or standard diagnostic (not least because of radiation exposure). The summarised evidence from guidelines can be used as a guideline for investment decisions.
Publication: Policy Brief No. 003/3. Update: https://eprints.aihta.at/1442/
Contact: Claudia Wild
Announcement
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you four new Fact Sheets.
Fact Sheet No. 125 (April 2023)
Niraparib/abiraterone acetate (Akeega®) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
Fact Sheet No. 126 (April 2023)
Ivosidenib (Tibsovo®, Tidhesco®) in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukaemia (AML)
Fact Sheet No. 127 (April 2023)
Ivosidenib (Tibsovo®) monotherapy for the treatment of locally advanced or metastatic cholangiocarcinoma
Fact Sheet No. 128 (April 2023)
Cemiplimab (Libtayo®) in combination with platinum-based chemotherapy for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)
Announcement
Perinatal and infant mental health care in Austria: A mapping of existing prevention, screening and care structures, with a specific focus on Tyrol
Up to 20% of women and 10% of men experience a mental illness during pregnancy and in the first year after birth. Due to the potentially severe effects on parents and child, there is an urgent need for rapid and effective care. This report provides a mapping of current care structures in Austria. The report is part of the FWF-funded research project "Co-designing perinatal mental health care in Tyrol". The report is to seen in connection with another report which has recently been published as part of the project and which describes the international recommendations on perinatal and infant mental health care (https://eprints.aihta.at/1420/1/HTA-Projektbericht_Nr.148.pdf).
Publication: HTA Projektbericht No. 151: https://eprints.aihta.at/1437/
Contact: Ingrid Zechmeister-Koss
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: Öffentliche Infrastruktur zur Überwindung des Marktversagens am Arzneimittelmarkt
- Evaluation von digitalen Gesundheitsanwendungen
- Gesundheitsökonomische Bewertung von „Personalisierter Medizin“
- Zahnprophylaxe: Zahnsteinentfernung und Politur
- Soziale Isolation und Einsamkeit im Alter
- Termine
- Themen-Vorschau
Announcement
Horizon Scanning of Medicines - Fact Sheets
We are pleased to introduce you one new Fact Sheets.
Fact Sheet No. 124 (February 2023)
Cipaglucosidase alfa (Pombiliti®) in combination with Miglustat for the treatment of adults with late-onset Pompe disease (acid alpha-glucosidase [GAA] deficiency)
